Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
SRRK Stock Forecast 2026-2027
$54.04
Current Price
$6.44B
Market Cap
Buy 18
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SRRK Price Targets
+29.5%
To High Target of $70.00
+7.3%
To Median Target of $58.00
-11.2%
To Low Target of $48.00
SRRK Price Momentum
-4.7%
1 Week Change
+15.1%
1 Month Change
+26.1%
1 Year Change
+22.7%
Year-to-Date Change
-7.6%
From 52W High of $58.49
+99.6%
From 52W Low of $27.07
๐ TOP ANALYST CALLS
Did SRRK Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if Scholar Rock is one of their latest high-conviction picks.
Latest SRRK Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, SRRK has a bullish consensus with a median price target of $58.00 (ranging from $48.00 to $70.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $54.04, the median forecast implies a 7.3% upside. This outlook is supported by 18 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SRRK Analyst Ratings
18
Buy
0
Hold
0
Sell
SRRK Price Target Range
Low
$48.00
Average
$58.00
High
$70.00
Current: $54.04
Latest SRRK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SRRK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 8, 2026 | Barclays | Etzer Darout | Overweight | Maintains | $55.00 |
| May 8, 2026 | HC Wainwright & Co. | Andres Y. Maldonado | Buy | Maintains | $65.00 |
| Apr 21, 2026 | Canaccord Genuity | Buy | Initiates | $N/A | |
| Apr 1, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Mar 16, 2026 | JP Morgan | Overweight | Maintains | $N/A | |
| Mar 4, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Mar 4, 2026 | BMO Capital | Outperform | Maintains | $N/A | |
| Mar 4, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| Mar 4, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Mar 4, 2026 | Piper Sandler | Overweight | Maintains | $N/A | |
| Mar 3, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 26, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jan 9, 2026 | Citigroup | Buy | Initiates | $N/A | |
| Jan 7, 2026 | UBS | Buy | Initiates | $N/A | |
| Dec 17, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Nov 18, 2025 | Wolfe Research | Outperform | Initiates | $N/A | |
| Nov 18, 2025 | JP Morgan | Overweight | Maintains | $N/A | |
| Nov 17, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Oct 20, 2025 | Truist Securities | Buy | Maintains | $N/A | |
| Oct 9, 2025 | B of A Securities | Buy | Initiates | $N/A |
Scholar Rock Holding Corporation (SRRK) Competitors
The following stocks are similar to Scholar Rock based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Scholar Rock Holding Corporation (SRRK) Financial Data
Scholar Rock Holding Corporation has a market capitalization of $6.44B with a P/E ratio of -16.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -138.9%.
Valuation Metrics
Market Cap
$6.44B
Enterprise Value
$6.28B
P/E Ratio
-16.4x
PEG Ratio
-0.7x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+7.4%
Current Ratio
8.6x
Debt/Equity
74.5x
ROE
-138.9%
ROA
-54.3%
๐ก SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Scholar Rock Holding Corporation (SRRK) Business Model
About Scholar Rock Holding Corporation
What They Do
Develops innovative biopharmaceuticals for serious diseases.
Business Model
Scholar Rock Holding Corporation utilizes a proprietary platform to develop monoclonal antibodies that target the TGFฮฒ superfamily, focusing on inhibiting the activation of growth factors. The company generates revenue through advancing its drug candidates, which are in various stages of clinical trials, aimed at treating conditions like spinal muscular atrophy and certain cancers.
Additional Information
Founded in 2012 and based in Cambridge, Massachusetts, Scholar Rock is addressing significant unmet medical needs in neuromuscular disorders, obesity, cancer, and fibrosis. Its key product candidates include apitegromab, SRK-181, SRK-373, and SRK-256, highlighting a diversified pipeline in critical therapeutic areas.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
289
CEO
Mr. David L. Hallal
Country
United States
IPO Year
2018
Website
www.scholarrock.comScholar Rock Holding Corporation (SRRK) Latest News & Analysis
Latest News
Quick Summary
Scholar Rock (NASDAQ: SRRK) will report Q2 2026 financial results on August 6, 2026, before market open, followed by a conference call at 8:00 a.m. ET. Details available on their website.
Why It Matters
Scholar Rock's upcoming financial results and conference call may influence investor sentiment and stock performance, providing insights into the company's growth and financial health.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Scholar Rock (NASDAQ: SRRK) will present new clinical data at the Cure SMA Annual Research & Clinical Care Meeting on June 24-26, 2026, focusing on spinal muscular atrophy and related diseases.
Why It Matters
New clinical data from Scholar Rock could influence market perception and stock performance, especially given the focus on rare diseases, which may attract investment interest and partnerships.
Source: Business Wire
Market Sentiment:
Neutral
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1 month ago
Quick Summary
Scholar Rock granted inducement equity awards totaling 134,345 shares to eleven new employees, including stock options for 50,936 shares and restricted stock units for 83,409 shares.
Why It Matters
Scholar Rock's granting of equity awards to new employees signals potential growth and aligns employee interests with shareholder value, which could impact stock performance positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Scholar Rock Holding Corporation (SRRK) presented at the Goldman Sachs 47th Annual Global Healthcare Conference, highlighting its developments and strategies in the healthcare sector.
Why It Matters
Scholar Rock's presentation at a major healthcare conference highlights its strategic initiatives and potential growth, influencing investor sentiment and stock performance in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Scholar Rock (NASDAQ: SRRK) will present at the Goldman Sachs Global Healthcare Conference on June 9, 2026, focusing on treatments for spinal muscular atrophy and related diseases.
Why It Matters
Scholar Rock's presentation at a major healthcare conference highlights its focus on SMA and neuromuscular diseases, potentially attracting investor interest and impacting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Scholar Rock (NASDAQ: SRRK) will present at the Jefferies Global Healthcare Conference in New York on June 3, 2026, at 11:40 a.m., focusing on treatments for spinal muscular atrophy and neuromuscular diseases.
Why It Matters
Scholar Rock's presentation at a major healthcare conference could indicate upcoming developments or partnerships, potentially impacting stock performance and investor sentiment in the biopharmaceutical sector.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About SRRK Stock
What is Scholar Rock Holding Corporation's (SRRK) stock forecast for 2027?
Based on our analysis of 6 Wall Street analysts, Scholar Rock Holding Corporation (SRRK) has a median price target of $58.00. The highest price target is $70.00 and the lowest is $48.00.
Is SRRK stock a good investment in 2027?
According to current analyst ratings, SRRK has 18 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $54.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SRRK stock?
Wall Street analysts predict SRRK stock could reach $58.00 in the next 12 months. This represents a 7.3% increase from the current price of $54.04. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Scholar Rock Holding Corporation's business model?
Scholar Rock Holding Corporation utilizes a proprietary platform to develop monoclonal antibodies that target the TGFฮฒ superfamily, focusing on inhibiting the activation of growth factors. The company generates revenue through advancing its drug candidates, which are in various stages of clinical trials, aimed at treating conditions like spinal muscular atrophy and certain cancers.
What is the highest forecasted price for SRRK Scholar Rock Holding Corporation?
The highest price target for SRRK is $70.00 from at , which represents a 29.5% increase from the current price of $54.04.
What is the lowest forecasted price for SRRK Scholar Rock Holding Corporation?
The lowest price target for SRRK is $48.00 from at , which represents a -11.2% decrease from the current price of $54.04.
What is the overall SRRK consensus from analysts for Scholar Rock Holding Corporation?
The overall analyst consensus for SRRK is bullish. Out of 6 Wall Street analysts, 18 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $58.00.
How accurate are SRRK stock price projections?
Stock price projections, including those for Scholar Rock Holding Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 3:20 PM UTC